Federico Pozzo

832 total citations
21 papers, 247 citations indexed

About

Federico Pozzo is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Federico Pozzo has authored 21 papers receiving a total of 247 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 9 papers in Immunology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Federico Pozzo's work include Chronic Lymphocytic Leukemia Research (20 papers), Lymphoma Diagnosis and Treatment (8 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Federico Pozzo is often cited by papers focused on Chronic Lymphocytic Leukemia Research (20 papers), Lymphoma Diagnosis and Treatment (8 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Federico Pozzo collaborates with scholars based in Italy, Germany and Switzerland. Federico Pozzo's co-authors include Valter Gattei, Antonella Zucchetto, Riccardo Bomben, Erika Tissino, Giovanni Del Poeta, Francesca Maria Rossi, Michele Dal Bo, Tamara Bittolo, Gianluca Gaïdano and Davide Rossi and has published in prestigious journals such as Blood, British Journal of Haematology and Leukemia.

In The Last Decade

Federico Pozzo

19 papers receiving 246 citations

Peers

Federico Pozzo
Jade Forster United Kingdom
Adam Albitar United States
Reina Improgo United States
Laura Wake United States
Jade Forster United Kingdom
Federico Pozzo
Citations per year, relative to Federico Pozzo Federico Pozzo (= 1×) peers Jade Forster

Countries citing papers authored by Federico Pozzo

Since Specialization
Citations

This map shows the geographic impact of Federico Pozzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Pozzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Pozzo more than expected).

Fields of papers citing papers by Federico Pozzo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Pozzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Pozzo. The network helps show where Federico Pozzo may publish in the future.

Co-authorship network of co-authors of Federico Pozzo

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Pozzo. A scholar is included among the top collaborators of Federico Pozzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Pozzo. Federico Pozzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mazzaro, Cesare, Marcella Visentini, Laura Gragnani, et al.. (2023). Persistence of monoclonal B‐cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus‐associated lymphoproliferative disorders. British Journal of Haematology. 203(2). 237–243. 3 indexed citations
2.
Pozzo, Federico, Idanna Innocenti, Francesco Autore, et al.. (2023). Measurable residual disease in chronic lymphocytic leukemia. Frontiers in Oncology. 13. 1112616–1112616. 4 indexed citations
3.
Mazzaro, Cesare, Riccardo Bomben, Laura Gragnani, et al.. (2022). Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy. Seminars in Hematology. 59(4). 177–182. 4 indexed citations
4.
Pozzo, Federico, Tamara Bittolo, Erika Tissino, et al.. (2022). Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond. Cancers. 14(12). 2997–2997. 10 indexed citations
5.
Vendramini, Elena, Riccardo Bomben, Federico Pozzo, et al.. (2022). KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders. Cancers. 14(3). 666–666. 19 indexed citations
6.
Pozzo, Federico, et al.. (2022). Integrin Signaling Shaping BTK-Inhibitor Resistance. Cells. 11(14). 2235–2235. 8 indexed citations
7.
Poeta, Giovanni Del, Luca Laurenti, Annalisa Chiarenza, et al.. (2020). Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. Haematologica. 106(9). 2345–2353. 9 indexed citations
8.
Pozzo, Federico, Tamara Bittolo, Erika Tissino, et al.. (2020). <i>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. Haematologica. 106(12). 3125–3135. 13 indexed citations
9.
Bomben, Riccardo, Federico Pozzo, Erika Tissino, et al.. (2020). An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. Cancers. 12(4). 894–894. 21 indexed citations
10.
Poeta, Giovanni Del, Luca Laurenti, Annalisa Chiarenza, et al.. (2018). Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). Blood. 132(Supplement 1). 4396–4396. 3 indexed citations
11.
Poeta, Giovanni Del, Massimiliano Postorino, Federico Pozzo, et al.. (2018). The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). Blood. 132(Supplement 1). 4397–4397. 2 indexed citations
12.
Pozzo, Federico, Tamara Bittolo, Elena Vendramini, et al.. (2017). NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. Leukemia. 31(11). 2407–2415. 46 indexed citations
13.
Pozzo, Federico, Tamara Bittolo, Elena Vendramini, et al.. (2017). NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY a MYC‐RELATED OVEREXPRESSION OF NUCLEOPHOSMIN‐1 AND RIBOSOME ASSOCIATED COMPONENTS. Hematological Oncology. 35(S2). 57–58.
14.
Bo, Michele Dal, Pietro Bulian, Riccardo Bomben, et al.. (2015). CD49d Prevails over the Novel Recurrent Mutations As Independent Prognosticator of Overall Survival in Chronic Lymphocytic Leukemia. Blood. 126(23). 1706–1706.
15.
Poeta, Giovanni Del, Michele Dal Bo, Francesco Buccisano, et al.. (2015). Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL). Blood. 126(23). 1718–1718. 1 indexed citations
16.
Bo, Michele Dal, Maria Ilaria Del Principe, Federico Pozzo, et al.. (2014). NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Annals of Hematology. 93(10). 1765–1774. 29 indexed citations
17.
Zucchetto, Antonella, Dania Benedetti, Erika Tissino, et al.. (2013). CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood. 122(19). 3317–3321. 38 indexed citations
18.
Pozzo, Federico, Michele Dal Bo, Nadia Peragine, et al.. (2013). Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. Journal of Hematology & Oncology. 6(1). 83–83. 17 indexed citations
19.
Poeta, Giovanni Del, Michele Dal Bo, Maria Ilaria Del Principe, et al.. (2012). Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia.. Blood. 120(21). 2870–2870. 1 indexed citations
20.
Pozzo, Federico, et al.. (2009). A Simple Multiplex Real-Time PCR Methodology for the SMN1 Gene Copy Number Quantification. Genetic Testing and Molecular Biomarkers. 13(1). 37–42. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026